IsoPlexis is Dedicated to the Identification of Cellular Drivers of Durable and Protective Immune Response to COVID-19
IsoPlexis has now announced several COVID-19 partnerships to utilize the single-cell immune profiling platform to help accelerate the development of potent therapeutics and durable vaccines.
The newly announced partnership with the Division of Infectious Diseases in the Department of Medicine at Columbia University is dedicated to using IsoPlexis’ Single-Cell Secretome immune profiling solutions to study the cellular drivers of durable and protective immune response to COVID-19. This partnership with a world-class vaccine production department is vital to accelerating the fight against COVID-19.
In previous published studies, IsoPlexis’ platform has identified polyfunctional cytokine responses from T cell and other immune cells that have predicted a variety of responses in both human and mouse studies in fields such as cancer immunology and infectious diseases.
Toward the beginning of the outbreak in the US, IsoPlexis partnered with the Institute for Systems Biology (ISB) as a part of the largest US-based COVID-19 consortium. The goal is to map functional immune responses at the single cell level to study COVID-19, data of which will be made public as soon as possible. Some of which has already been shared in a recent webinar from James Heath, President of the ISB.
Recent Continued Press Coverage Highlights IsoPlexis’ Dedication to COVID-19 Research
Recently, IsoPlexis’ partnerships were featured by GenomeWeb and Nature Biotechnology. “A singular view of COVID-19” in Nature Biotechnology focused on the ways that different single-cell technologies and analyses are accelerating the fight against COVID-19.
“Proteomic analysis can also fill in critical gaps concerning cell type and function…A Seattle-based research consortium headed by the Swedish Medical Center, the Institute for Systems Biology and Merck is also applying a host of multi-omic analytical techniques to blood specimens collected from patients with COVID-19, including a platform developed by IsoPlexis that employs microchip-based immunoassays to profile secreted cytokines and other signaling molecules from individual immune cells. ‘It basically allows you to perform 35-plex analysis of cytokine secretion from viable single cells,’ says James Heath, president of the Institute for Systems Biology and cofounder of IsoPlexis.”
IsoPlexis’ platform has already been used to help profile the immune response of COVID-19 patients to better understand why some patients experience more severe disease. The Seattle consortium obtained preliminary data showing that exhausted T cells are accumulating in more severe COVID-19 cases compared to more moderate cases and that these markers appear to be the most proliferative. Being able to identify markers like this are essential to gaining insight into the immune response to this novel disease and in accelerating the development of therapeutics and vaccines.
A recent article published in GenomeWeb highlighted IsoPlexis’ partnership with Columbia University to aid in the development of a durable and potent vaccine for COVID-19.
“We are looking forward to our partnership with Columbia University in the fight against COVID-19.” IsoPlexis CEO Sean Mackay said in a statement. “This work will provide critical functional insights into the mechanisms of protective and durable immune response to COVID-19, especially with regards to the activity of T cells.”
Dr. Moriya Tsuji, Professor of Medicine at Columbia University, has previously utilized IsoPlexis’ platform in several published vaccine studies for diseases such as malaria. Dr. Tsuji’s humanized mouse model is an important contribution to the vaccine world and will help to create more durable and potent vaccines, especially when it comes to COVID-19.
Learn more about how IsoPlexis is helping researchers accelerate therapeutic and vaccine development for COVID-19 in this webinar.